MD1374F2 - Anticorpi monoclonali imunostimulatori, procedeu de obtinere a acestora, linii celulare, metoda de tratare a maladiilor si compozitie farmaceutica - Google Patents
Anticorpi monoclonali imunostimulatori, procedeu de obtinere a acestora, linii celulare, metoda de tratare a maladiilor si compozitie farmaceuticaInfo
- Publication number
- MD1374F2 MD1374F2 MD96-0296A MD960296A MD1374F2 MD 1374 F2 MD1374 F2 MD 1374F2 MD 960296 A MD960296 A MD 960296A MD 1374 F2 MD1374 F2 MD 1374F2
- Authority
- MD
- Moldova
- Prior art keywords
- proposed
- antibody
- monoclonal
- pharmaceutical composition
- lymphocytes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL10850194A IL108501A (en) | 1994-01-31 | 1994-01-31 | Antibodies and pharmaceutical compositions containing them |
| PCT/US1995/001137 WO1995020605A1 (en) | 1994-01-31 | 1995-01-30 | Immuno-stimulatory monoclonal antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD1374F2 true MD1374F2 (ro) | 1999-12-31 |
| MD1374G2 MD1374G2 (ro) | 2000-09-30 |
Family
ID=11065761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MD96-0296A MD1374G2 (ro) | 1994-01-31 | 1995-01-30 | Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5897862A (ro) |
| EP (1) | EP0742795B1 (ro) |
| JP (1) | JP3478398B2 (ro) |
| CN (1) | CN1052733C (ro) |
| AT (1) | ATE171461T1 (ro) |
| AU (1) | AU693526B2 (ro) |
| CA (1) | CA2182289C (ro) |
| DE (1) | DE69504955T2 (ro) |
| DK (1) | DK0742795T3 (ro) |
| EE (1) | EE03285B1 (ro) |
| ES (1) | ES2124533T3 (ro) |
| FI (1) | FI963004A (ro) |
| IL (1) | IL108501A (ro) |
| LT (1) | LT4225B (ro) |
| LV (1) | LV11624B (ro) |
| MD (1) | MD1374G2 (ro) |
| MX (1) | MX9603080A (ro) |
| NO (1) | NO317020B1 (ro) |
| RU (1) | RU2155190C2 (ro) |
| WO (1) | WO1995020605A1 (ro) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL129299A0 (en) * | 1999-03-31 | 2000-02-17 | Mor Research Applic Ltd | Monoclonal antibodies antigens and diagnosis of malignant diseases |
| IL145926A0 (en) | 2001-10-15 | 2002-07-25 | Mor Research Applic Ltd | Peptide epitopes of mimotopes useful in immunomodulation |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| JP4409430B2 (ja) | 2002-07-03 | 2010-02-03 | 小野薬品工業株式会社 | 免疫賦活組成物 |
| DE10311248A1 (de) * | 2003-03-14 | 2004-09-30 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Humaner monoklonaler Antikörper |
| WO2006021955A2 (en) * | 2004-08-23 | 2006-03-02 | Mor Research Applications Ltd. | Use of bat monoclonal antibody for immunotherapy |
| CN117534755A (zh) | 2005-05-09 | 2024-02-09 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| CN104548091A (zh) | 2008-02-11 | 2015-04-29 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| MD3972C2 (ro) * | 2009-03-11 | 2010-07-31 | Ион МЕРЕУЦЭ | Remediu şi metodă de tratament al stărilor precanceroase |
| CA2840018C (en) | 2011-07-24 | 2019-07-16 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| US9580504B1 (en) | 2013-11-07 | 2017-02-28 | Curetech Ltd. | Pidilizumab monoclonal antibody therapy following stem cell transplantation |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| CA2960824A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of alk inhibitors |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| SG10201906059VA (en) | 2015-07-30 | 2019-08-27 | Macrogenics Inc | Pd-1-binding molecules and methods of use thereof |
| PE20181322A1 (es) | 2015-09-01 | 2018-08-14 | Agenus Inc | Anticuerpo anti-pd1 y sus metodos de uso |
| WO2017058859A1 (en) | 2015-09-29 | 2017-04-06 | Celgene Corporation | Pd-1 binding proteins and methods of use thereof |
| CR20180234A (es) | 2015-11-03 | 2018-09-11 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a pd-1 y sus usos |
| EP3389714A4 (en) | 2015-12-14 | 2019-11-13 | MacroGenics, Inc. | BISPECIFIC MOLECULES HAVING IMMUNOREACTIVITY TO PD-1 AND CTLA-4 AND METHODS OF USE |
| WO2017220990A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 antibodies |
| JP2019534859A (ja) | 2016-09-19 | 2019-12-05 | セルジーン コーポレイション | Ｐｄ−１結合タンパク質を使用して白斑を治療する方法 |
| EA201990747A1 (ru) | 2016-09-19 | 2019-10-31 | Способы лечения иммунных нарушений с применением белков, связывающих pd–1 | |
| BR112019011582A2 (pt) | 2016-12-07 | 2019-10-22 | Agenus Inc. | anticorpos e métodos de utilização dos mesmos |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| US20240294651A1 (en) | 2023-01-30 | 2024-09-05 | Kymab Limited | Antibodies |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5182368A (en) * | 1986-06-13 | 1993-01-26 | Ledbetter Jeffrey A | Ligands and methods for augmenting B-cell proliferation |
-
1994
- 1994-01-31 IL IL10850194A patent/IL108501A/en not_active IP Right Cessation
-
1995
- 1995-01-30 DK DK95910891T patent/DK0742795T3/da active
- 1995-01-30 JP JP52021095A patent/JP3478398B2/ja not_active Expired - Lifetime
- 1995-01-30 US US08/380,857 patent/US5897862A/en not_active Expired - Lifetime
- 1995-01-30 CA CA002182289A patent/CA2182289C/en not_active Expired - Lifetime
- 1995-01-30 RU RU96116984/13A patent/RU2155190C2/ru active
- 1995-01-30 DE DE69504955T patent/DE69504955T2/de not_active Expired - Lifetime
- 1995-01-30 WO PCT/US1995/001137 patent/WO1995020605A1/en not_active Application Discontinuation
- 1995-01-30 MD MD96-0296A patent/MD1374G2/ro unknown
- 1995-01-30 EE EE9600107A patent/EE03285B1/xx unknown
- 1995-01-30 EP EP95910891A patent/EP0742795B1/en not_active Expired - Lifetime
- 1995-01-30 ES ES95910891T patent/ES2124533T3/es not_active Expired - Lifetime
- 1995-01-30 CN CN95192406A patent/CN1052733C/zh not_active Expired - Lifetime
- 1995-01-30 AT AT95910891T patent/ATE171461T1/de active
- 1995-01-30 AU AU18686/95A patent/AU693526B2/en not_active Expired
-
1996
- 1996-07-29 FI FI963004A patent/FI963004A/fi unknown
- 1996-07-29 MX MX9603080A patent/MX9603080A/es not_active IP Right Cessation
- 1996-07-29 NO NO19963168A patent/NO317020B1/no not_active IP Right Cessation
- 1996-07-30 LT LT96-115A patent/LT4225B/lt not_active IP Right Cessation
- 1996-09-06 LV LVP-96-317A patent/LV11624B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT96115A (en) | 1997-05-26 |
| IL108501A0 (en) | 1994-05-30 |
| MD1374G2 (ro) | 2000-09-30 |
| LT4225B (en) | 1997-10-27 |
| FI963004A0 (fi) | 1996-07-29 |
| CN1052733C (zh) | 2000-05-24 |
| JPH09508390A (ja) | 1997-08-26 |
| EE03285B1 (et) | 2000-08-15 |
| AU693526B2 (en) | 1998-07-02 |
| CA2182289A1 (en) | 1995-08-03 |
| CA2182289C (en) | 2003-10-21 |
| NO963168D0 (no) | 1996-07-29 |
| EP0742795B1 (en) | 1998-09-23 |
| US5897862A (en) | 1999-04-27 |
| LV11624A (en) | 1996-12-20 |
| RU2155190C2 (ru) | 2000-08-27 |
| DK0742795T3 (da) | 1999-06-14 |
| NO963168L (no) | 1996-09-27 |
| DE69504955D1 (de) | 1998-10-29 |
| FI963004A (fi) | 1996-09-27 |
| WO1995020605A1 (en) | 1995-08-03 |
| LV11624B (en) | 1997-06-20 |
| DE69504955T2 (de) | 1999-05-27 |
| JP3478398B2 (ja) | 2003-12-15 |
| ES2124533T3 (es) | 1999-02-01 |
| NO317020B1 (no) | 2004-07-26 |
| EP0742795A1 (en) | 1996-11-20 |
| AU1868695A (en) | 1995-08-15 |
| CN1145077A (zh) | 1997-03-12 |
| IL108501A (en) | 1998-10-30 |
| ATE171461T1 (de) | 1998-10-15 |
| MX9603080A (es) | 1998-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD1374F2 (ro) | Anticorpi monoclonali imunostimulatori, procedeu de obtinere a acestora, linii celulare, metoda de tratare a maladiilor si compozitie farmaceutica | |
| JP3769014B2 (ja) | 多段カスケード型追加免疫ワクチン | |
| Handman et al. | Stage-specific, strain-specific, and cross-reactive antigens of Leishmania species identified by monoclonal antibodies | |
| RU96116984A (ru) | Иммуностимуляторные моноклональные антитела | |
| Moroz et al. | Cell-surface immunoglobulin of human thymus cells and its biosynthesis in vitro | |
| KR920703036A (ko) | 자가면역 및 악성 질환 치료제로서의 t 세포 수용체 펩타이드 | |
| WO1995020605A9 (en) | Immuno-stimulatory monoclonal antibodies | |
| JP2002531123A5 (ro) | ||
| ZA891861B (en) | Monoclonal antibodies | |
| CA2284079A1 (en) | Immunotoxins and methods of inducing immune tolerance | |
| PT1331944E (pt) | Utilização de anticorpos monoclonais específicos para cd28 para a estimulação de células sanguíneas que não comportam qualquer cd28 | |
| Van Laar et al. | Effects of inoculation with attenuated autologous T cells in patients with rheumatoid arthritis | |
| Segal et al. | Specific blocking in vitro of antibody synthesis by affinity labelling reagents | |
| JPH10505325A (ja) | 治療剤としてのｔ細胞に対する抗体 | |
| JPH01501793A (ja) | 透明帯に対する免疫化による避妊のための方法 | |
| Eig et al. | Complete inhibition of the expression of an idiotype by a mechanism of B-cell dominance. | |
| EP0282343A2 (en) | Method to stimulate the immune response to specific antigens | |
| EP0525570A2 (en) | Anti-idiotypic antibodies that mimic TNF | |
| US7118924B2 (en) | Method for producing human antibodies in SCID mice which uses dendritic cells pulsed with antigen-antibody complexes and antigen-antibody complexes as immunizing agents | |
| ES2000615A6 (es) | Procedimiento para la preparacion del anticuerpo monoclonal designado como mak 436-15 del isotipo igg3" | |
| Brams et al. | Antigen-specific IgG responses from naive human splenocytes: in vitro priming followed by antigen boost in the SCID mouse | |
| Cobbold et al. | Immunosuppression with monoclonal antibodies—rules for effective serotherapy | |
| Sinclair et al. | Antibody-mediated immunosuppression of a cytotoxic cell response not involving a simple antigen-masking mechanism | |
| RU2227748C2 (ru) | Тарапевтический агент для лечения кахексии | |
| Simon et al. | Immunoregulation by mouse T cell clones III. Cloned H‐Y‐specific cytotoxic T cells secrete a soluble mediator (s) that inhibits cytotoxic responses by acting on both Lyt‐2− and L3T4− lymphocytes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD99 | Pending application |